Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Batimastat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 14/20 | 0.80 |
| ▸ | MMP2 known ✓ | P08253 | 8/20 | 0.80 |
| ▸ | MMP3 known ✓ | P08254 | 6/20 | 0.80 |
| ▸ | MMP7 known ✓ | P09237 | 4/20 | 0.80 |
| ▸ | MMP9 known ✓ | P14780 | 4/20 | 0.80 |
| ▸ | MMP12 known ✓ | P39900 | 1/20 | 0.53 |
| ▸ | FCER2 | P06734 | 12/20 | 0.80 |
| ▸ | MMP8 | P22894 | 4/20 | 0.80 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.80 |
| ▸ | MMP13 | P45452 | 3/20 | 0.80 |
| ▸ | MMP14 | P50281 | 3/20 | 0.80 |
| ▸ | MMP20 | O60882 | 1/20 | 0.53 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.53 |
| ▸ | TNF | P01375 | 1/20 | 0.53 |
| ▸ | MMP10 | P09238 | 1/20 | 0.53 |
| ▸ | MMP15 | P51511 | 1/20 | 0.53 |
| ▸ | MMP16 | P51512 | 1/20 | 0.53 |
| ▸ | MMP25 | Q9NPA2 | 1/20 | 0.53 |
| ▸ | MMP26 | Q9NRE1 | 1/20 | 0.53 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Batimastat SCHEMBL22803645 | 0.90 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL4332 | 0.90 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL12336015 | 0.90 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL4333 | 0.90 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL10052355 | 0.90 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL12561510 | 0.90 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL17521974 | 0.90 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| Batimastat SCHEMBL20793035 | 0.90 | MMP1 (1.00) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL8385113 | 0.87 | ADAM17 (0.69) | MMP1FCER2MMP2MMP3MMP7 | |
| SCHEMBL25602214 | 0.85 | MMP1 (0.82) | MMP1FCER2MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144604-A2 | METHODS FOR THE TREATMENT OF LIVER DISEASES USING SPECIFIED MATRIX METALLOPROTEINASE (MMP) INHIBITORS | Conatus Pharmaceuticals, Inc. (US) | 2010-01-20 | — | — | EP | claimed |
| WO-2008106166-A2 | METHODS FOR THE TREATMENT OF LIVER DISEASES USING SPECIFIED MATRIX METALLOPROTEINASE (MMP) INHIBITORS | CONATUS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | claimed |
| WO-2008106167-A1 | COMBINATION THERAPY COMPRISING MATRIX METALLOPROTEINASE INHIBITORS AND CASPASE INHIBITORS FOR THE TREATMENT OF LIVER DISEASES | CONATUS PHARMACEUTICALS, INC. (US) | 2008-09-04 | — | — | WO | claimed |
| WO-2021076712-A1 | EARLY MANAGEMENT AND PREVENTION OF SEPSIS AND SEPSIS-LIKE SYNDROMES | OPHIREX, INC. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2002080891-A1 | USE OF A TNF INHIBITOR FOR THE TREATMENT OF LOW BACK PAIN | A+ SCIENCE INVEST AB (SE) | 2002-10-17 | — | — | WO | disclosed |